Back

In vivo CRISPR screening identifies NF1/RASA1/TP53 co-mutations and downstream MEK signaling as a common key mechanism of sinonasal tumorigenesis

Vu, K. P.; Gunti, S.; Viswanathan, R.; Nandal, A.; Larkin, R.; Cho, S.; Zou, J.; Ramolia, S.; Hoke, A. T. K.; Barbosa, S. M.; Gallia, G. L.; Rooper, L. M.; Floudas, C. S.; Cheng, H.; Miller, C. N.; Guest, M. R.; Notaro, M.; Raziuddin, A.; Sun, Z.; Wu, X.; Faraji, F.; Lechner, M.; Comoglio, F.; Edmondson, E. F.; Chari, R.; London, N. R.

2025-05-23 cancer biology
10.1101/2025.05.19.654661 bioRxiv
Show abstract

Genomic alterations driving tumorigenesis in sinonasal malignancies remain largely unexplored. Here, we perform an in vivo loss-of-function screen using a pooled custom single-guide library delivered to the sinonasal cavity by adeno-associated virus vector to identify cancer driver genes across diverse sinonasal malignancies. This approach yielded sinonasal malignancies with diverse histologies, including sinonasal squamous cell carcinoma, adenocarcinoma, poorly differentiated sinonasal carcinoma, and sinonasal neuroendocrine tumors characteristic of olfactory neuroblastoma. Surprisingly, rather than observing distinct sgRNA profiles across sinonasal tumor subtypes, common recurrent mutations were identified in Nf1 (79%), Rasa1 (74%), and Trp53 (68%) across malignancies with distinct histologies. Utilizing an orthogonal approach, we confirmed that Nf1/Trp53 were required for sinonasal tumorigenesis. Given that loss-of-function in NF1 and RASA1 may lead to increased Ras activity and downstream MEK signaling, we tested small molecule targeting of the RAS-MAPK pathway in sinonasal malignancies. Indeed, both tumor cell lines derived from our loss-of-function approach as well as from human sinonasal malignancies displayed significant sensitivity to MEK inhibition in standard in vitro culture and organoid models. These findings demonstrate that loss of NF1 and RASA1-mediated Ras-GAP activity leads to Ras activation and downstream MEK signaling which is a potential common target throughout major sinonasal tumor subtypes.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Molecular Cancer
14 papers in training set
Top 0.1%
14.1%
2
Nature Communications
4913 papers in training set
Top 19%
9.9%
3
Cell Reports
1338 papers in training set
Top 6%
6.7%
4
Scientific Reports
3102 papers in training set
Top 20%
6.2%
5
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 21%
3.5%
6
Molecular Therapy
71 papers in training set
Top 0.8%
3.5%
7
eLife
5422 papers in training set
Top 30%
3.0%
8
Neuro-Oncology
30 papers in training set
Top 0.3%
2.6%
9
Cancer Research Communications
46 papers in training set
Top 0.2%
2.6%
50% of probability mass above
10
Cell Genomics
162 papers in training set
Top 2%
2.3%
11
Cancer Cell
38 papers in training set
Top 0.8%
2.1%
12
Gastroenterology
40 papers in training set
Top 1%
1.7%
13
Cancers
200 papers in training set
Top 3%
1.5%
14
Cell
370 papers in training set
Top 13%
1.5%
15
Cell Reports Medicine
140 papers in training set
Top 4%
1.5%
16
PLOS ONE
4510 papers in training set
Top 59%
1.3%
17
Cancer Research
116 papers in training set
Top 3%
1.2%
18
Molecular Cancer Therapeutics
33 papers in training set
Top 0.5%
1.2%
19
Cancer Letters
32 papers in training set
Top 0.4%
1.2%
20
Genome Medicine
154 papers in training set
Top 6%
1.2%
21
iScience
1063 papers in training set
Top 23%
1.1%
22
JCI Insight
241 papers in training set
Top 6%
0.9%
23
Neoplasia
22 papers in training set
Top 0.5%
0.9%
24
Communications Biology
886 papers in training set
Top 19%
0.9%
25
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1.0%
0.8%
26
ACS Central Science
66 papers in training set
Top 2%
0.8%
27
Science Advances
1098 papers in training set
Top 28%
0.8%
28
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.8%
29
Cell Reports Methods
141 papers in training set
Top 5%
0.7%
30
Cancer Discovery
61 papers in training set
Top 2%
0.7%